The FDA has approved the first generic version of Restasis, according to a press release.
Cyclosporine ophthalmic emulsion 0.05% increases tear production in patients with dry eye disease. The generic option is sponsored by Mylan Pharmaceuticals.
“Restasis [Allergan] has been approved for use in the U.S. for nearly 20 years, but until today, there was no approved generic product of this drug that can help the millions of Americans who suffer from dry eyes,” Sally Choe, PhD, director of the Office of Generic Drugs in FDA’s Center for Drug Evaluation and Research, said in the